Squarepoint’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,200
Closed -$636K – 5050
2026
Q2
$636K Buy
+11,200
New +$497K ﹤0.01% 3233
2025
Q2
– Sell
-24,300
Closed -$435K – 5070
2025
Q1
$435K Buy
+24,300
New +$493K ﹤0.01% 3432

Other funds holding TVTX

Squarepoint's TVTX Position: Q3 2026 in Review

Squarepoint increased its Travere Therapeutics (TVTX) stake by 209% in Q3 2026, buying an estimated $14M and bringing the position to 339,833 shares worth $20M. The position accounts for 0.02% of the portfolio, ranked #684.

Squarepoint first reported a position in TVTX in Q4 2015 and has held it in 34 quarters since. 317 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Squarepoint held 339,833 shares of Travere Therapeutics worth $20M as of Q3 2026.
  • Squarepoint bought 230,026 Travere Therapeutics shares in Q3 2026, an estimated $14M.
  • Travere Therapeutics made up 0.02% of Squarepoint's portfolio in Q3 2026, its #684 holding.
  • Squarepoint first reported a position in Travere Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • 317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.